FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02641639 |
|
Recruitment Status :
Terminated
(Interim analysis failed to show efficacy benefit)
First Posted : December 29, 2015
Last Update Posted : March 22, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Platinum Resistant Ovarian Cancer | Drug: Fosbretabulin tromethamine Drug: Placebo | Phase 2 Phase 3 |
This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC). Subjects with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer will be randomized 1:1 to receive PCC plus bevacizumab and CA4P or PCC plus bevacizumab and placebo. Subjects will be stratified by selected chemotherapy (PLD vs. paclitaxel), platinum free interval (< 3 vs. 3 to 6 months from last platinum therapy to subsequent progression), and line of therapy (2nd vs. 3rd). This is a 2-part study, consisting of a Phase 2, exploratory study (Part 1) followed by a Phase 3, pivotal study (Part 2). Both parts of the study will have similar overall design. Approximately 80 subjects will be randomized into Part 1 and approximately 356 subjects will be randomized into Part 2.
All subjects randomized will receive bevacizumab 10 mg/kg intravenously (IV) on Days 1 and 15, repeated every 4 weeks (q4wk) and PCC with paclitaxel 80 mg/m2 IV on Days 1, 8, 15 and 22, repeated q4wk, or paclitaxel 80 mg/m2 IV on Days 1, 8, 15, repeated q4wk or PLD 40 mg/m2 IV on Day 1, repeated q4wk. Subjects in the Treatment Arm will also receive CA4P 60 mg/m2 on the same day as bevacizumab (Days 1 and 15, repeated q4wk), while subjects in the Control Arm will receive placebo on those days.
Order of dosing will follow the guidance listed below during this study when bevacizumab and CA4P / Placebo are dosed the same day as PCC,
- Bevacizumab followed by CA4P / Placebo followed after 1-3 hours by paclitaxel,
- PLD followed by bevacizumab followed by CA4P / Placebo Subjects will continue randomized treatment until disease progression, unacceptable toxicity, investigator decision, withdrawal of consent, or sponsor discontinues study for any reason. Subjects will undergo tumor assessments (RECIST) at baseline and every 8 weeks and CA-125 levels at baseline and every 4 weeks.
The primary endpoint is PFS. Secondary endpoints include ORR, OS, proportion of subjects who remain progression free at 6, 9, and 12 months, and safety. Endpoints will be compared between the Treatment Arm and the Control arm. The study duration is estimated to last approximately 3 years.
This study will have 2 parts with the same overall design. Part 1 will enroll up to approximately 80 subjects and will include multiple interim analyses to test the safety and efficacy assumptions in this specific subject population. Upon meeting certain efficacy criteria in Part 1, the protocol will be amended and additional sites added in order to enroll an additional 356 subjects into Part 2 of the study. Subjects enrolled in Part 2 will be analyzed separately and used as a stand-alone confirmatory efficacy study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 91 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| Actual Study Start Date : | June 2016 |
| Actual Primary Completion Date : | October 2017 |
| Actual Study Completion Date : | October 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Fosbretabulin tromethamine
Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and CA4P
|
Drug: Fosbretabulin tromethamine
CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
Other Name: Fosbretabulin Combretastatin A4-Phosphate, CA4P |
|
Placebo Comparator: Placebo
Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and placebo
|
Drug: Placebo
Saline for infusion
Other Name: Saline for infusion |
- Progression free survival [ Time Frame: Minimum 12 months ]The primary efficacy parameter in this study is statistically meaningful PFS, defined as the time from the date of randomization until patient discontinuation or death from any cause.
- Improvement in objective response rate [ Time Frame: Minimum 12 Months ]Improvement in objective response rate (ORR), using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Gynecologic Cancer Intergroup (GCIG) cancer antigen-125 (CA-125) criteria
- Evaluation of overall survival (OS) [ Time Frame: Minimum 12 Months ]Evaluation of overall survival (OS)
- Proportion of subjects who remain progression-free at 6, 9, and 12 months [ Time Frame: Minimum 12 Months ]Assessment of the proportion of subjects who remain progression-free at 6, 9, and 12 months on the regimen of PCC plus bevacizumab and CA4P compared with PCC plus bevacizumab and placebo
- Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo [ Time Frame: Minimum 12 Months ]To evaluate the Incidence of Treatment-Emergent Adverse Events of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo as measured by aggregate reporting of the number of patient with abnormal findings on (physical exams, vital signs, laboratory measures, ECG, Eastern Cooperative Oncology Group (ECOG) performance status (PS)) and/or analysis of the incidence of adverse events (AEs) using the National Cancer Institute (NCI)-Common Terminology Criteria for AEs (CTCAE) version 4.03.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion:
- Signed informed consent form (ICF)
- Age ≥ 18 years (Age ≥ 19 years if required by local regulatory authorities)
- ECOG PS of 0-1
- Histologically or cytologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer in recurrent stage
- prOC (platinum-resistant ovarian cancers) defined as progression within > 1 to < 6 months (+ 2 weeks) of completing previous cycle of primary platinum-based therapy, or during or within < 6 months (+ 2 weeks) of starting additional platinum based therapies
- Received ≥ 1 but ≤ 3 prior platinum-based regimens
- Measurable disease according to RECIST 1.1
- Left ventricular ejection fraction (LVEF) greater than or equal to at least 45% at baseline assessment if subject is receiving PLD, and/or anthracycline is a concomitant medication
- No evidence of active (progressing) brain metastasis. (Treated brain metastasis allowed with a posttreatment magnetic resonance imaging (MRI) or Computed Tomography (CT) of brain showing no active (progressing) brain metastasis). Treatment of brain metastasis may include surgery, radiosurgery (linear accelerator (LINAC), gamma knife), or whole brain irradiation. Surgery for brain metastasis must be > 8 weeks from study entry
- Hemoglobin > 9 g/dl. Erythroid growth factors should not have been used in the 2 weeks prior to study entry. Red blood cell transfusions are permitted to maintain the hemoglobin level > 9 g/dl
- Adequate bone marrow function in the investigator's opinion
-
Adequate hepatic function defined by the following:
- Total bilirubin < 2 x Upper Limit of Normal (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN for the referenced lab (< 5 X ULN for subjects with liver metastases)
-
Adequate renal function defined by the following:
- Serum creatinine < 2 X ULN for the referenced lab
- Subjects of childbearing potential must have a negative serum pregnancy test prior to study entry and must be practicing a highly effective form of contraception
- At least 2 weeks since prior radiotherapy and has recovered from any Grade 3 toxicities
- Life expectancy ≥ 12 weeks
Exclusion:
- Subjects who have received prior CA4P therapy
-
Previously having failed treatment with bevacizumab combined with the intended PCC.
- For clarity: Investigators should not select a bevacizumab + PCC combination for the FOCUS trial if the patient has previously failed that same regimen, however they may select a new PCC regimen to combine with bevacizumab. For example, a patient who failed bevacizumab + weekly paclitaxel would be allowed to enroll in FOCUS only if they are assigned to bevacizumab + PLD for the study.
- Previous treatment with greater than three traditional chemotherapy treatment regimens
- Untreated brain metastasis or leptomeningeal brain metastasis
- Solid organ or bone marrow transplant
- Primary platinum-refractory disease (defined as progression during dosing or within one (1) month of completing the last cycle of patients first platinum-containing regimen)
- > Grade 2 peripheral neuropathy
- Current thrombotic or hemorrhagic disorder/event or history of prior event within 6 months of start of Screening
- History of prior cerebrovascular event, (including transient ischemic attack) within 6 months of start of Screening
- Recent history (within 6 months of start of Screening) of angina pectoris, myocardial infarction (including non-Q wave MI), or NYHA Class III and IV congestive heart failure
- History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (<60 bpm), heart block (excluding 1st degree block, benign PR interval prolongation only), congenital long QT syndrome or new ST segment elevation or depression or new Q wave on ECG
- Known uncontrolled HIV infection
- Uncontrolled, clinically significant active infection
- Serious non-healing wound, ulcer or bone fracture
- Subjects with known hypersensitivity to any of the components of CA4P, paclitaxel, PLD, or bevacizumab (paclitaxel and PLD dependent on whether PI plans they will be dosed with that PCC)
- Subjects who are currently or planning on receiving concurrent investigational therapy or who have received investigational therapy for any indication within 30 days of the first scheduled day of dosing
- Subjects with any other intercurrent medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a subject's ability to provide informed consent, cooperate and participate in the study, or to interfere with the interpretation of the study results
- Subjects with other invasive malignancies, with the exception of non-melanoma skin cancer, or with previous cancer treatment that contraindicates this protocol therapy within last 3 years
- Prior radiation therapy to the pelvis or abdomen within 4 weeks of entry into the study
- History of fistula, gastrointestinal (GI) perforation or intra-abdominal abscess, or invasive disease/metastases of the bowel which in the investigators opinion may increase the risk of GI perforation with bevacizumab treatment.
-
Uncontrolled hypertension (HTN)
- Sustained BP greater than 150 mmHG SBP / 100 mmHG DBP
- Uncontrolled elevated proteinuria levels in the investigator's opinion
- Corrected QT interval ([QTc] Fridericia) > 480 ms
- Significant vascular disease or recent peripheral arterial thrombosis
- Subjects with active bleeding or pathologic conditions that carry high risk of bleeding
- Subjects who are pregnant or lactating
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02641639
Show 40 study locations
| Study Director: | Harish Dave, MD | Medical Monitor |
| Responsible Party: | Mateon Therapeutics |
| ClinicalTrials.gov Identifier: | NCT02641639 |
| Other Study ID Numbers: |
OX4325 |
| First Posted: | December 29, 2015 Key Record Dates |
| Last Update Posted: | March 22, 2018 |
| Last Verified: | March 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases |
Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Fosbretabulin Combretastatin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |